Net Loss: Net loss attributable to common stockholders for the third quarter of 2024 was $ (3.1) million, or $ (1.92) per share, compared to net income of $0.5 million, or $4.86 per share, for the ...

Initiation of Phase 1b Study of GT-02287 in Parkinson's patients expected by end of 2024 BETHESDA, Md., Nov. 14, 2024 (GLOBE ...

Preclinical and clinical data demonstrate that BXQ-350 is a potent allosteric activator of wild type and mutated glucocerebrosidase (GCase). A key mutation in the GBA gene, which encodes GCase, ...

Using analysis from an open-label, long-term treatment study of the RNS ® System, Rapport will present key new data on the correlation between the reduction in long episode (LE) frequency (abnormal ...

This clinical trial is a randomized, double-blind study designed to enroll 120 patients across four treatment groups. The ...